8-K: Celularity Inc. Announces Preliminary Revenue for Q4 2023 and Q1 2024, Hosts Investor Day

Celularity Inc. reports preliminary net revenue of approximately $12.1 million for Q4 2023 and $14.8 million for Q1 2024, alongside hosting an Investor and Analyst Research & Development Day.

Summary

• Celularity Inc. has released preliminary, unaudited revenue figures for the fourth quarter of 2023 and the first quarter of 2024.
• The company expects to report approximately $12.1 million in net revenue for the quarter ended December 31, 2023.
• For the quarter ended March 31, 2024, Celularity anticipates net revenue of about $14.8 million.
• These revenues are derived from biomaterial product sales and biobanking services.
• The full financial results for both periods are still being finalized and are subject to change following audits and reviews.
• Celularity hosted an Investor and Analyst Research & Development Day on May 21, 2024, to provide business updates.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is showing revenue growth, but the results are preliminary and unaudited. The investor day is a positive sign of engagement.

Positives

• The company's revenue increased from $12.1 million in Q4 2023 to $14.8 million in Q1 2024, indicating growth.
• Celularity is actively engaging with investors and analysts through an R&D day.

Negatives

• The financial results are preliminary and unaudited, meaning they are subject to change.
• The full financial results for Q4 2023 and Q1 2024 are not yet finalized.

Risks

• The reported revenue figures are preliminary and may be adjusted after the completion of audits and reviews.
• The company's financial condition is not fully detailed in this report, as it only provides revenue figures.
• There is a risk that the final financial results could differ materially from the preliminary figures.

Future Outlook

The company will continue to finalize its financial results for Q4 2023 and Q1 2024, and will provide updates as they become available. Celularity will also continue to engage with investors and analysts.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of the company.

Industry Context

The announcement of preliminary revenue figures and the hosting of an investor day are typical activities for a publicly traded company in the biotechnology sector. This allows the company to keep investors informed of its progress and financial performance.

Comparison to Industry Standards

• It is difficult to compare Celularity's preliminary results to industry standards without more detailed financial information.
• Companies like Fate Therapeutics and CRISPR Therapeutics are also in the cell therapy space, but their financial results and business models may differ significantly.
• A more detailed analysis would require a full set of financial statements and a deeper understanding of Celularity's specific market and competitive landscape.

Stakeholder Impact

• Shareholders will be interested in the preliminary revenue figures and the company's future performance.
• Analysts will use the information to update their models and recommendations.
• Employees may be impacted by the company's financial performance and future plans.

Next Steps

• Celularity will finalize its financial results for Q4 2023 and Q1 2024.
• The company will continue to engage with investors and analysts.
• The company will provide updates as they become available.

Key Dates

Keywords

Celularity, revenue, biomaterial, biobanking, financial results, investor day, preliminary, Q4 2023, Q1 2024